精神在线您现在的位置:  >> NaSSA合理应用文献研究平台 >> 文献服务 >> 抑郁、焦虑与睡眠障碍 >> 临床研究 >> 文献正文
米氮平治疗抑郁症患者期间其睡眠结构、睡眠脑电波分光光谱组成、皮质醇、促肾上腺皮质激素、生长激素、泌乳素、褪黑激素、生长激素释放肽和瘦蛋白夜间分泌的变化,以及地塞米松抑制试验加CRH兴奋试验的变化
文献服务】【告诉好友】【打印此文】【关闭窗口
题目(Title)Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine.

著者(Authors)】 Schmid DA, Wichniak A, Uhr M, Ising M, Brunner H, Held K, Weikel JC, Sonntag A, Steiger A.
来源(Source)】 Neuropsychopharmacology. 2006 Apr;31(4):832-44.
关键词(Keywords)】 mirtazapine

摘要(Abstract)】:

The noradrenergic and specific serotoninergic antidepressant mirtazapine improves sleep, modulates hormone secretion including blunting of hypothalamic-pituitary-adrenocortical (HPA) activity, and may prompt increased appetite and weight gain. The simultaneous investigation of sleep electroencephalogram (EEG) and hormone secretion during antidepressive treatment helps to further elucidate these effects. We examined sleep EEG (for later conventional and quantitative analyses) and the nocturnal concentrations of cortisol, adrenocorticotropin (ACTH), growth hormone (GH), prolactin, melatonin and the key factors of energy balance, ghrelin, and leptin before and after 28 days of treatment of depressed patients (seven women, three men, mean age 39.9+/-4.2 years) with mirtazapine. In addition, a sleep EEG was recorded at day 2 and the dexamethasone-corticotropin-releasing hormone (DEX-CRH) test was performed to assess HPA activity at days -3 and 26. Psychometry and mirtazapine plasma concentrations were measured weekly. Already at day 2, sleep continuity was improved. This effect persisted at day 28, when slow-wave sleep, low-delta, theta and alpha activity, leptin and (0300-0700) melatonin increased, and cortisol and ghrelin decreased. ACTH and prolactin remained unchanged. The first two specimens of GH collected after the start of quantitative EEG analysis were reduced at day 28. The DEX-CRH test showed, at day 26, a blunting of the overshoot of ACTH and cortisol found at day -3. The Hamilton Depression score decreased from 32.1+/-7.3 to 15.5+/-6.7 between days -1 and 28. A weight gain of approximately 3 kg was observed. This unique profile of changes is compatible with the action of mirtazapine at 5-HT-2 receptors, at presynaptic adrenergic alpha 2 receptors, at the HPA system, and on ghrelin and leptin.


  • 上一篇文献: 没有了
  • 下一篇文献:

  • 相关文献
    米氮平引起帕金森病人快速动眼期睡眠行为障碍
    抗抑郁药与射精:米氮平与帕罗西汀固定剂量下的双盲随机对照研究
    一篇三步曲实例综述,强调米氮平在降低许多药物引起的焦虑、激越、失眠、抑郁和性功能障碍的临床和药物应用
    交互式电讯记录不同剂量给药方案下米氮平对病人警觉和睡眠的影响
    米氮平对于抑郁症病人睡眠连续性和结构急性效应的初步研究
    米氮平对抑郁症患者睡眠多导图变量的影响
    米氮平,但非氟伏沙明,使抑郁症患者对可乐定治疗的变钝的REM睡眠反应标准化:抑郁症患者α-2肾上腺素受体低敏感性的意义
    米氮平对于睡眠影响的由青年健康志愿者参加的安慰剂对照双盲研究
    睡眠生理测定条件下米氮平和氟西汀对重性抑郁伴有失眠病人的效应比较
    米氮平的耐受性和安全性
    服用米氮平的抑郁症门诊患者的性功能状况
    米氮平所治疗患者的性功能改变:与抑郁症患者有关的一项国际化多中心的前瞻性观察研究的原始数据



    精神在线网 复旦大学医学院精神卫生学系 合办
    本站专业医学信息和服务仅供中国医疗专业人士参考

    © 精神在线网 PsyCard.Com
    精神/心理医学专业信息网络平台、博客、论坛
    全站文章索引-SiteMap